Leerink Partnrs Has Negative Outlook for REGN Q1 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for shares of Regeneron Pharmaceuticals in a note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $7.07 per share for the quarter, down from their previous forecast of $7.56. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS and FY2026 earnings at $35.16 EPS.

Several other research firms have also recently commented on REGN. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Bernstein Bank decreased their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $966.88.

Remove Ads

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $37.19 during mid-day trading on Thursday, reaching $573.45. 1,547,645 shares of the company were exchanged, compared to its average volume of 687,961. Regeneron Pharmaceuticals has a 12 month low of $572.00 and a 12 month high of $1,211.20. The stock has a market cap of $62.69 billion, a PE ratio of 14.98, a PEG ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $676.70 and a 200 day moving average of $779.13.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the prior year, the business earned $11.86 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the business. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $36,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.